Esperion Therapeutics Inc News - ESPR

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience...

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

U.S. Futures Rise as Investors Await Fed Rate Decision; Oil Prices Drop

U.S. index futures rose in Thursday’s pre-market session following Donald Trump’s victory, which sent...

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million...

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company...

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

ANN ARBOR, Mich., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that one featured...

👍️0

FACT-MASTER 21 hours ago

Accumulation in progress, imo.

Trading here has taken a turn to the positive, imo, ask walls methodically being taken out.

Hope i don't get side smacked for stating that analysis.

👍 1

FACT-MASTER 1 day ago

Sounds like today's Jefferies conference was a bit more optimistic.

I'm not a member on st but often read that board, many good posters there.

https://www.thelion.com/bin/aio_msg.cgi?cmd=search&symbol=espr

FACT-MASTER 2 days ago

Nice move today with good volume!

Looks like bidding was strong today, that's weird,,,, for ESPR.

👍 1

FACT-MASTER 2 days ago

Thanks for that information, however that being the case, management failed to use the opportunity to bridge some trust with the investing community by re-confirming a commitment to building shareholder value / working in the best interests of shareholders / pledging to cease share based executive compensation until the company reaches profitability / outline a plan to profitability / detail expense restraint / and outlining a plan to profitability.

I concur that 2024 has been a pivotal year of accomplishment, however the marketplace appears to be skeptical of ESPR mgmt. The current share price and market cap suggests a loss of confidence in ESPR mgmt., imo.

👍️0

Gregg4 2 days ago

Yup someone is buying trying to keep under wraps

👍️0

nsomniyak 3 days ago

The interview was sponsored by Esperion. That means the interviewer was given a predetermined script written by Esperion, he was not free to ask "top of mind" questions from a shareholder's point of view.

There were no questions about stock performance because Esperion did not want to answer any such questions.

👍️0

FACT-MASTER 3 days ago

ESPR: On deck for November 19/24

Jefferies London Healthcare Conference

https://www.esperion.com/events/event-details/jefferies-london-healthcare-conference-3

Will it be a re-hash of the poster presentations this past weekend or does Sheldon have something new to lift the spirits of long term shareholders, we will see tomorrow.

Interesting late day trading the last couple of sessions.

👍 1

Gregg4 3 days ago

I agree never hard questions

👍️0

FACT-MASTER 3 days ago

https://www.fiercehealthcare.com/sponsored/2024-pivotal-year-fight-against-cardiovascular-disease

I'm always surprised that the interviewer never asks the respondant about the share price performance. If it been such a pivotal year of accomplishments, why has the stock lost approx. 50% since January 1/24?? Sheldon, can you comment on that and please expand on where you think the market cap should be and/or what exactly is the problem with ESPR stock performance?

👍 1

FACT-MASTER 3 days ago

ESPR: Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

https://finance.yahoo.com/news/esperion-highlights-exploratory-data-clear-153000058.html

Sellers just can't sell enough, level II ask keeps loading. Level II = hopeless for ESPR, imo.

👍 1

FACT-MASTER 5 days ago

Esperion Corporate presentation November 2024

https://www.esperion.com/static-files/c900cfb6-ec24-45cf-81a5-ee14d1836a53

Looks like a NDA in Canada during November (slide 11) - no big deal, imo.

👍 1

FACT-MASTER 1 week ago

The Vanguard Group reported 10,816,762 shares held as of June 30/24.

https://www.nasdaq.com/market-activity/stocks/espr/institutional-holdings

The Vanguard Group reported 13,043,077 shares held as of September 30/24

https://archive.fast-edgar.com/20241104/AB22M222Z222VJD222222ZO2LQ2ST322B262/UnitedStates_13G__EsperionTh.txt

Increase of 2,226,315 shares in the 3rd quarter

👍 1

Gregg4 1 week ago

Hope so been long almost 4 years

👍️0

FACT-MASTER 1 week ago

It seems something big is in the works.

Haven't seen Level II act the way it did today, ask in the low 2.50-2.53 were getting repeatedly annihilated.

Could be a major partnering, or a buyout in the works, imo.

👍️0

Gregg4 1 week ago

Yes one trade almost a million shares

👍️0

FACT-MASTER 1 week ago

AH volume on fire!

https://www.nasdaq.com/market-activity/stocks/espr/after-hours

FACT-MASTER 1 week ago

Strong to the close.

Looking good!, imo.

👍 1

FACT-MASTER 2 weeks ago

WOW! nice move north!

Level II bid looking pretty strong.

Pleasantly surprised here this morning!

👍 1

FACT-MASTER 2 weeks ago

Nascar promotional collaboration 2024 has failed, imo

https://www.esperion.com/news-releases/news-release-details/rfk-esperion-therapeutics-announce-2024-promotional-schedule

It's time for ESPR mgmt. to get serious and employ competent, dedicated sales reps who know how to get the job done!

https://www.youtube.com/shorts/zlkURHOXkKs

👍 1

FACT-MASTER 2 weeks ago

ESPR: Form 10-Q

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024046307/espr-20240930.htm

👍️0

FACT-MASTER 2 weeks ago

ESPR: No funds available to redeem convert.notes, imo.

Cash and cash equivalents $ 144,717,000

and losing 30$ million per quarter - does not look good, imo

👍️0

FACT-MASTER 2 weeks ago

ESPR: For what??? Losing money?? ( in bold below)

2024 Financial Outlook

The Company reiterates its full year 2024 operating expense guidance, which is expected to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation.

and here under SG&A

The increase is primarily related to the ramp up of our sales force associated with our commercial launch in addition to bonus payments and promotional costs.

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024045984/espr-20241107.htm

ESPR mgmt. spending appears to be out of control. imo.

Only positive today is that ESPR is not sub$2, imo.

👍️0

FACT-MASTER 2 weeks ago

ESPR: Official earnings SEC filing

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024045984/espr-20241107.htm

Problem areas, imo:

Selling, general and administrative 39,975,000
Interest expense (15,082,000)

Whatever they are spending money on in the "Selling, general and administrative" like NasCar and sales reps - it's not working.

Overall prognosis is poor, and financials are weak.

No news on the converts in the near term will mean no profitability anytime soon, imo.

👍 1

FACT-MASTER 2 weeks ago

ESPR:

👍️0

FACT-MASTER 2 weeks ago

$2.25 rejected.

Perpetual wall on the ask at $2.25.

What are we anticipating for tomorrow's earnings call?

It seems positive imo, that the earnings release is prior to the open, as opposed to releasing the earnings after the close.

👍 1

FACT-MASTER 4 weeks ago

scriptstrend on ST shares some good points.

https://stocktwits.com/scriptstrend2024/message/590178774

ESPR mgmt. needs to pay attention:

https://www.youtube.com/shorts/aZctsTD1iJY

👍 1

Gregg4 4 weeks ago

Guess we will see 11/7

👍️0

FACT-MASTER 4 weeks ago

I'm not expecting anything spectacular from the 3rd quarter results.

ESPR management team has failed long term investors by squandering shareholder value.
From what i have seen here, their expenditures are not translating into sales.

Great clinical trial results / great product / stock price barely holding a measly $2 dollars says ESPR management has failed - big time, imo.

👍️0

Gregg4 4 weeks ago

Just dreaming probably nothing but I'm hoping start of a long march upward

👍️0

FACT-MASTER 4 weeks ago

FACT-MASTER 4 weeks ago

Esperion to Report Third Quarter 2024 Financial Results on November 7

https://finance.yahoo.com/news/esperion-report-third-quarter-2024-120000845.html

👍️0

FACT-MASTER 1 month ago

https://finance.yahoo.com/news/millennium-management-llcs-strategic-reduction-230255195.html

As i mentioned previously, there could be something that is repulsive regarding ESPR mgmt.
A fund just doesn't dump that many shares at a bargain price for no reason. Something made then lose interest big time, and the only thing i can think of is ESPR mgmt.

Did this fund take a huge loss upon selling that huge portion of ESPR stock?

Not good, imo.

FACT-MASTER 1 month ago

I think it would be logical, imo, if ESPR was going to make a move to redeem the convertible notes, to do so on the issue/maturity anniversary date - Nov.15.

If they were to redeem them this year that would be one year prior to the final maturity of November 15/25.

That makes sense, imo, so if they are going to move on the convertible notes this year, we should be hearing about details between now and say November 5/10ish.

👍️0

glenn1919 2 months ago

ESPR.........................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783

FACT-MASTER 2 months ago

Another great day here at ESPR!

AH $2.18

👍️0

Gregg4 2 months ago

Yes thanks still need to make up ground

👍️0

FACT-MASTER 2 months ago

Comprende amigo.

I think your on the right track now, i do the same, only buy stock, stay out of options / etf's etc.

Your off to a great start today!

👍️0

Gregg4 2 months ago

No I lost massive cash in options past few months August and September I sold all my shares and went to options last fall when we hit .70 did very we’ll be played the game too long got burned three years makes u impatient so I started over with stock only

👍️0

FACT-MASTER 2 months ago

Congrats on that! looks like you picked a good day to get in.

Did you previously sell out, and now just bought back in?

I thought you were a dedicated bagholder like the rest of us, (lol)

👍️0

Gregg4 2 months ago

Back in all stock 57,620 $1.65

👍️0

Gregg4 2 months ago

I get it too if company so great why is it at $1.65 still

👍️0

FACT-MASTER 2 months ago

I must say, i like the conviction you have about ESPR, along with the other guys on st - i see some of those guys are still buying too.

If i didn't have any shares, i would be buying at this level too, however i'v lost some confidence in mgmt and just in a holding pattern for now.

I'm hoping for news on redemption of the convertible notes. That is the remaining obstacle, imo, before this story elevates to a higher level.

All the best with your purchases tomorrow.

👍️0

Gregg4 2 months ago

I’m buying this tomorrow both fists 60k shares

👍️0

FACT-MASTER 2 months ago

RED...., again - what else is new with ESPR

👍️0

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Esperion Therapeutics Inc (ESPR)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ESPR News

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

U.S. Futures Rise as Investors Await Fed Rate Decision; Oil Prices Drop

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

Esperion to Report Third Quarter 2024 Financial Results on November 7

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

ESPR Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Esperion Therapeutics Inc (ESPR) News

Esperion Therapeutics Inc (ESPR)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

ESPR News

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

U.S. Futures Rise as Investors Await Fed Rate Decision; Oil Prices Drop

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions

Esperion to Report Third Quarter 2024 Financial Results on November 7

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

ESPR Discussion

Your Recent History

Company

Business

Popular

Get The App